Alone or in combination w/ HMG-CoA reductase inhibitor (statin), as adjunctive therapy to diet for the reduction of elevated total cholesterol, LDL cholesterol, apolipoprotein B (Apo B) & non-HDL-cholesterol in patients w/ primary (heterozygous familial & non-familial) hyperlipidemia. In combination w/ fenofibrate, as adjunctive therapy to diet for the reduction of total-C, LDL-C, Apo B, & non-HDL-C in adult patients w/ mixed hyperlipidemia. In combination w/ atorvastatin or simvastatin, for the reduction of elevated total-C & LDL-C levels in patients w/ homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments (eg, LDL apheresis) or if such treatment are unavailable. Adjunctive therapy to diet for the reduction of elevated sitosterol & campesterol levels in patients w/ homozygous familial sisterolemia. In combination w/ simvastatin, to reduce the risk of major CV events in patients w/ chronic kidney disease. In combination w/ statins, to reduce the risk of CV events (CV death, non-fatal MI & stroke, hospitalization for unstable angina or need for revascularization) in patients w/ CHD; prevention of CV disease.